Cite

HARVARD Citation

    Baker, C. et al. (2019). Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial. Diabetes, obesity & metabolism. 21 (11), pp. 2440-2449. [Online]. 
  
Back to record